<?xml version="1.0" encoding="UTF-8"?>
<p id="p0620">In a non-randomized study of 67 patients, affected by COVID-19, a lower mortality rate was shown to occur in patients treated with umifenovir (arbidol hydrochloride), as compared with patients who did not receive the drug 
 <xref rid="b0855" ref-type="bibr">[171]</xref>. Moreover, in a small group of patients without invasive ventilation, an interesting study showed that oral arbidol plus lopinavir/ritonavir was associated with a significant negative conversion rate of coronavirus test in 7-day and 14-day, with respect to the lopinavir/ritonavir therapy group 
 <xref rid="b0870" ref-type="bibr">[174]</xref>. Umifenovir is not a protease inhibitor itself and inhibits membrane fusion of the viral envelope by targeting the interaction of the S protein with ACE2.
</p>
